Literature DB >> 27189675

The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors.

John M Keith1, Mark S Tichenor2, Richard L Apodaca2, Wei Xiao2, William M Jones2, Mark Seierstad2, Joan M Pierce2, James A Palmer2, Michael Webb2, Mark J Karbarz2, Brian P Scott2, Sandy J Wilson2, Michelle L Wennerholm2, Michele Rizzolio2, Raymond Rynberg2, Sandra R Chaplan2, J Guy Breitenbucher2.   

Abstract

The SAR of brain penetration for a series of heteroaryl piperazinyl- and piperadinyl-urea fatty acid amide hydrolase (FAAH) inhibitors is described. Brain/plasma (B/P) ratios ranging from >4:1 to as low as 0.02:1 were obtained through relatively simple structural changes to various regions of the heteroaryl urea scaffold. It was not possible to predict the degree of central nervous system (CNS) penetration from the volumes of distribution (Vd) obtained from pharmacokinetic (PK) experiments as very high Vds did not correlate with high B/P ratios. Similarly, calculated topological polar surface areas (TPSAs) did not consistently correlate with the degree of brain penetration. The lowest B/P ratios were observed for those compounds that were significantly ionized at physiological pH. However, as this class of compounds inhibits the FAAH enzyme through covalent modification, low B/P ratios did not preclude effective central target engagement.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BBB; Blood brain barrier; Covalent inhibition; FAAH; Heteroaryl urea; Rat PK; Target engagement

Mesh:

Substances:

Year:  2016        PMID: 27189675     DOI: 10.1016/j.bmcl.2016.05.001

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Computational chemistry at Janssen.

Authors:  Herman van Vlijmen; Renee L Desjarlais; Tara Mirzadegan
Journal:  J Comput Aided Mol Des       Date:  2016-12-19       Impact factor: 3.686

2.  Synthesis, molecular docking, and biological evaluation of novel 2-pyrazoline derivatives as multifunctional agents for the treatment of Alzheimer's disease.

Authors:  Oya Unsal-Tan; Tuba Tüylü Küçükkılınç; Beyza Ayazgök; Ayla Balkan; Keriman Ozadali-Sari
Journal:  Medchemcomm       Date:  2019-05-09       Impact factor: 3.597

Review 3.  Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022.

Authors:  Paweł Kozyra; Monika Pitucha
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.